You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Details for New Drug Application (NDA): 214275


✉ Email this page to a colleague

« Back to Dashboard


NDA 214275 describes UPTRAVI, which is a drug marketed by Actelion and is included in two NDAs. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the UPTRAVI profile page.

The generic ingredient in UPTRAVI is selexipag. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the selexipag profile page.
Summary for 214275
Tradename:UPTRAVI
Applicant:Actelion
Ingredient:selexipag
Patents:4
Pharmacology for NDA: 214275
Mechanism of ActionProstacyclin Receptor Agonists
Suppliers and Packaging for NDA: 214275
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
UPTRAVI selexipag POWDER;INTRAVENOUS 214275 NDA Actelion Pharmaceuticals US, Inc. 66215-718 66215-718-01 1 VIAL, SINGLE-DOSE in 1 CARTON (66215-718-01) / 10 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrength1.8MG/VIAL
Approval Date:Jul 29, 2021TE:RLD:Yes
Patent:⤷  Get Started FreePatent Expiration:Oct 31, 2026Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Patent:⤷  Get Started FreePatent Expiration:Aug 1, 2030Product Flag?YSubstance Flag?YDelist Request?
Patent:⤷  Get Started FreePatent Expiration:Aug 12, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links